Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: Three Oncologics, A New Migraine Preventive, And First LPAD Antibiotic Clear US FDA

Keeping Track Feature image

Related Content

US FDA Joins Chorus Of Concerns About Results Of GAIN Act

Feb 05 2018

Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion

Apr 08 2018

"Site License" Reimbursement Model For Limited Use Antibacterials Being Explored By US FDA, CMS

Jul 31 2018

Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J

Sep 23 2018

Allergan/Richter’s Antipsychotic Vraylar Offers New Mechanism Of Action

Sep 18 2015

Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too

Sep 24 2017

Allergan Seeks Quick Vraylar Turnaround After US FDA Refuses To File

Sep 26 2017

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted

Aug 13 2018

Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product

Aug 16 2018

Insmed’s Amikacin Gains US FDA Panel Nod For Refractory Lung Disease

Aug 08 2018

Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks

Dec 29 2016

Other ASCO 2018 Highlights – It’s Not All IO

May 18 2018

Verastem Sees Phase III Success With PIK3 Inhibitor Dropped By AbbVie

Sep 06 2017

Achaogen Questioning Whether Others Will Pursue LPAD Pathway After Zemdri Misses Out

Jun 27 2018

Infinity Doesn't Sugarcoat Disappointing Duvelisib Data; Cuts R&D Staff To Preserve Cash

Jun 15 2016

Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales

May 03 2018

Cidara To Take Rezafungin Into Phase III In Two Severe Infection Indications

Mar 19 2018

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack

Jul 02 2018

Keeping Track: Mylan Wins First US FDA Approval For Neulasta Biosimilar, But Lands A CRL For Insulin Glargine; Genentech Nabs Broad Full Approval For Venclexta, PV Indication For Rituxan

Jun 08 2018

Surprise Failure for Intra-Cellular Therapies’ Schizophrenia Drug Sends Shares Tumbling

Sep 29 2016

Related Companies

Regeneron Pharmaceuticals, Inc.

Sanofi

Pfizer Inc.

Verastem, Inc.

Eli Lilly and Company

Insmed Incorporated

Intra-Cellular Therapies, Inc.

Neurelis, Inc.

Allergan plc

Eisai Co., Ltd.

DMK Pharmaceuticals Corp.

Samsung Bioepis Co., Ltd.

Cidara Therapeutics, Inc.

PARI GmbH

Teva Pharmaceutical Industries Ltd.

AbbVie Inc.

Gilead Sciences, Inc.

Novartis AG

Amicus Therapeutics, Inc.

Infinity Pharmaceuticals, Inc.

Kaléo Pharmaceutical Inc.

Viatris Inc.

Novartis AG

GW Pharmaceuticals plc

Biocodex

Aquestive Therapeutics, Inc.

Neurelis, Inc.

Amgen, Inc.

Boehringer Ingelheim GmbH

Merck & Co., Inc.

Additional Topics

United States Drug Review Biosimilars Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window